GlaxoSmithKline: Gastroparesis trials

The registry lists 11 Gastroparesis studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 5Phase 2 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With GastroparesisCompletedNCT02210000Phase 2Results posted
• Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE StudyTerminatedNCT01934192Phase 2Results posted
• A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric EmptyingCompletedNCT01602549Phase 2Results posted
• Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With GastroparesisCompletedNCT01262898Phase 2Results posted
• FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese VolunteersCompletedNCT01294566Phase 1
• A Study to Evaluate the Pharmacokinetics and Absolute Bioavailability of GSK962040 Given as an Oral Dose Simultaneously With an Intravenous Microtracer Dose of [14C]-GSK962040 in Healthy VolunteersCompletedNCT01267071Phase 1
• GSK962040 Drug-drug Interaction Study With KetoconazoleCompletedNCT01039974Phase 1
• Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed IntoleranceCompletedNCT01039805Phase 2
• The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With GastroparesisCompletedNCT00861809Phase 2
• Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.CompletedNCT00733551Phase 1
• A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040CompletedNCT00562848Phase 1